On September 10, 2026, BioLineRx Ltd. and Hemispherian AS announced they will present encouraging preclinical efficacy data for GLIX1 and details regarding its Phase 1/2a trial design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) in Rome. GLIX1 is a first-in-class, oral TET2 activator ta...

Compugen Ltd. (Nasdaq: CGEN) filed a Form 6-K on September 10, 2026, reporting the results of its 2026 Annual General Meeting of Shareholders. The company announced that all proposals brought before the shareholders at the Meeting were approved by the requisite majority vote. While the filing does not detail the specif...

Helus Pharma (Nasdaq: HELP), formerly known as Cybin Inc., announced that its Chief Executive Officer, Michael Halstead, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The event is scheduled for Wednesday, September 16, 2026, in New York City. The company is a clinic...

Clearmind Medicine Inc. (Nasdaq: CMND) reported its unaudited condensed interim consolidated financial results for the three and nine months ended July 31, 2026. For the nine-month period, the company recorded a net loss of $6,809,527, significantly higher than the $3,169,141 loss in the prior year period. Operating ex...